Subclinical Hypothyroidism

Table of Contents

1. What Subclinical Hypothyroidism Means
2. Causes
3. Symptoms and What to Expect
4. Cardiovascular and Metabolic Risks
5. To Treat or Not to Treat — The Central Debate
6. Pregnancy and Subclinical Hypothyroidism
7. Levothyroxine Treatment — Practical Guide
8. Monitoring Without Treatment — Watchful Waiting
9. Nutritional and Lifestyle Factors
10. Key Research Papers
11. Featured Videos
12. Connections

What Subclinical Hypothyroidism Means

To understand subclinical hypothyroidism, you need to understand the feedback loop that controls thyroid function. The pituitary gland, a small structure at the base of your brain, constantly monitors the level of thyroid hormones in your blood. When levels dip even slightly, the pituitary releases more thyroid-stimulating hormone to signal the thyroid to produce more hormone. When levels are adequate, thyroid-stimulating hormone falls back.

In subclinical hypothyroidism, the thyroid is producing enough T4 and T3 to keep blood levels within the normal range — but only because the pituitary is sending an abnormally strong signal to make it happen. Thyroid-stimulating hormone is elevated; free T4 and free T3 are normal. It is, in a sense, compensated hypothyroidism: the system is working harder than it should to maintain normal output.

Staging by Thyroid-Stimulating Hormone Level

Physicians and guidelines distinguish two grades of subclinical hypothyroidism based on how high thyroid-stimulating hormone has climbed:

• Mild SCH (Grade 1): thyroid-stimulating hormone between 4.5 and 10 mIU/L. This is by far the most common presentation. The majority of patients have no significant symptoms, and a large proportion normalize spontaneously without treatment.
• Severe SCH (Grade 2): thyroid-stimulating hormone above 10 mIU/L. This carries a higher risk of cardiovascular complications, more frequent symptoms, and a greater likelihood of progression to overt hypothyroidism. Most guidelines recommend treatment at this level.

Natural History — Many Cases Resolve on Their Own

One of the most important and underappreciated facts about subclinical hypothyroidism is that it often goes away without treatment. Studies show that 40 to 50 percent of patients with thyroid-stimulating hormone between 4.5 and 10 mIU/L spontaneously normalize within one to two years. This is a critical piece of information for treatment decisions: starting levothyroxine immediately after a single abnormal thyroid-stimulating hormone result means treating many people whose thyroid would have corrected itself.

The Normal Range Debate

There is ongoing scientific discussion about whether the current upper limit of normal for thyroid-stimulating hormone — typically set at 4.0 to 4.5 mIU/L in most laboratory reference ranges — is actually too high. Some researchers argue that when you exclude people with subclinical autoimmune thyroid disease (positive thyroid peroxidase, or TPO, antibodies) from the population used to establish reference ranges, the true upper limit for a healthy thyroid is closer to 2.5 mIU/L. This debate has real clinical implications: a thyroid-stimulating hormone of 3.5 is "normal" by current standards but might be suboptimal in a woman trying to conceive, for instance. This remains unsettled.

Lab Variation — One Result Is Not Enough

Thyroid-stimulating hormone values can vary by 0.5 to 1.0 mIU/L in the same person measured on different days, at different times of day, or on different laboratory platforms. Guidelines call for confirming a single mildly elevated thyroid-stimulating hormone result — especially in the 4.5 to 6 range — with a repeat test before any treatment is started. Thyroid-stimulating hormone is also physiologically higher in winter, in the early morning, and during illness or recovery from illness. These sources of variation are real and often overlooked.

Back to Table of Contents

Causes

The most important question when subclinical hypothyroidism is found is: what is causing it? The answer shapes both prognosis and management.

Hashimoto's Thyroiditis

Hashimoto's thyroiditis (autoimmune thyroiditis) is the most common cause of subclinical hypothyroidism in iodine-sufficient countries. The immune system produces antibodies against thyroid proteins — most commonly anti-thyroid peroxidase antibodies (TPO-Ab) and anti-thyroglobulin antibodies (TgAb). These slowly damage thyroid tissue over years. Testing for TPO antibodies is important because their presence predicts a higher rate of progression to overt hypothyroidism: roughly 4 to 5 percent per year in TPO-positive patients, versus about 2 percent per year in antibody-negative patients.

Structural Causes

• Prior thyroid surgery: Partial thyroidectomy that leaves insufficient functioning thyroid tissue is a common cause of permanent subclinical and overt hypothyroidism.
• Post-radioiodine therapy: Radioactive iodine treatment for Graves' disease or toxic nodules frequently results in subclinical or overt hypothyroidism, sometimes months to years after treatment.

Medications — A Major and Often Missed Cause

Several common drugs can elevate thyroid-stimulating hormone and are a known cause when SCH is found on routine labs:

• Amiodarone: The most important drug cause. Amiodarone is a cardiac antiarrhythmic that is approximately 37 percent iodine by weight. It causes thyroid dysfunction — either hypothyroidism or hyperthyroidism — in 14 to 18 percent of patients. It also blocks the conversion of T4 to the more active T3. Any patient on amiodarone with an elevated thyroid-stimulating hormone needs careful endocrine evaluation.
• Lithium: Used in bipolar disorder. Lithium blocks thyroid hormone release and can cause both goiter and hypothyroidism. Regular thyroid monitoring is standard practice for people taking lithium.
• Tyrosine kinase inhibitors: Cancer drugs such as sunitinib and sorafenib commonly cause thyroid dysfunction, often hypothyroidism, through multiple mechanisms including impaired blood supply to the thyroid.
• Immune checkpoint inhibitors: Pembrolizumab, nivolumab, and other immunotherapy drugs used in cancer can trigger immune-mediated thyroiditis, leading to transient hyperthyroidism followed by hypothyroidism. This is increasingly common as these drugs are used more widely.
• Interferon alpha: Used in hepatitis C and certain cancers; can trigger autoimmune thyroid disease.
• Excess iodine supplements: Paradoxically, very high iodine intake can suppress thyroid function through the Wolff-Chaikoff effect — a transient inhibition of thyroid hormone synthesis. Most people escape this effect, but those with underlying autoimmune thyroid disease may not. Kelp supplements can deliver unpredictably large iodine doses.

Transient Causes

Some cases of subclinical hypothyroidism represent a transient phase of recovery from thyroid inflammation:

• Postpartum thyroiditis: A common condition affecting 5 to 10 percent of women in the first year after delivery. It typically causes transient hyperthyroidism followed by transient hypothyroidism before the thyroid returns to normal in most cases. Thyroid-stimulating hormone may be elevated for several months.
• Subacute (de Quervain's) thyroiditis: A painful viral thyroiditis that follows a similar pattern of initial thyrotoxicosis followed by a hypothyroid phase. Most patients recover full thyroid function within 6 to 12 months.
• Silent thyroiditis: Similar pattern to postpartum thyroiditis but not related to pregnancy; may follow viral illness.

Back to Table of Contents

Symptoms and What to Expect

If you have been told you have subclinical hypothyroidism and you feel unwell, you are not imagining it — but the scientific picture is genuinely complicated. The honest truth is that the research does not consistently show that mild SCH causes the symptoms patients commonly attribute to it.

The Symptom Challenge

The classic symptoms of hypothyroidism — fatigue, weight gain, cold intolerance, constipation, brain fog, depression, hair thinning, dry skin, slow heart rate — are also present in roughly half the general population for reasons completely unrelated to thyroid function. Studies that have compared symptom scores between people with subclinical hypothyroidism and people with entirely normal thyroid-stimulating hormone levels consistently find only weak correlations between thyroid-stimulating hormone elevation and symptom burden in the mild SCH range (thyroid-stimulating hormone 4.5 to 10 mIU/L).

This does not mean patients are wrong. It means the symptoms are non-specific, and that thyroid-stimulating hormone alone is not a reliable predictor of who will feel better with treatment. Confirming that symptoms are genuinely thyroid-related — rather than due to sleep apnea, depression, anemia, vitamin D deficiency, perimenopause, or a dozen other common conditions — is important before committing to lifelong thyroid hormone replacement.

When Symptoms Are More Likely Thyroid-Related

Certain features make it more plausible that symptoms in a patient with SCH are genuinely driven by thyroid dysfunction:

• Thyroid-stimulating hormone above 10 mIU/L: The higher the thyroid-stimulating hormone, the more likely that thyroid function is meaningfully impaired and that symptoms will respond to treatment.
• Positive TPO antibodies: Autoimmune thyroid disease can cause systemic inflammation that contributes to fatigue and cognitive symptoms independently of hormone levels.
• Objective measurable changes: A resting heart rate below 60, elevated total cholesterol or low-density lipoprotein (LDL), myxedema (puffy face or hands), or abnormal reflexes — these findings on examination or labs point to genuine physiological effects of thyroid underactivity.
• Symptoms that respond dramatically to a levothyroxine trial: A careful 3-month trial of low-dose levothyroxine, with systematic symptom tracking before and after, can clarify whether thyroid status is actually driving symptoms.
• Younger adults: People in their 30s and 40s with SCH and symptoms have a better evidence base for treatment benefit than elderly patients.

Cognitive Effects

Many patients with SCH report memory problems and difficulty concentrating. Observational studies have shown associations between elevated thyroid-stimulating hormone and mild cognitive decline, particularly in younger and middle-aged adults. However, the 2017 TRUST randomized controlled trial — the largest and most rigorous study to date on treating SCH in older adults — found no benefit of levothyroxine on cognitive outcomes in patients aged 65 and older with thyroid-stimulating hormone up to 19.99 mIU/L. This is an important finding, though it may not apply to younger patients.

Back to Table of Contents

Cardiovascular and Metabolic Risks

The cardiovascular and metabolic consequences of subclinical hypothyroidism are the strongest argument for treatment — especially in younger patients and those with thyroid-stimulating hormone above 10.

Lipid Effects

Thyroid hormones regulate cholesterol metabolism, and even mild thyroid underactivity can shift the lipid profile in an unfavorable direction. Meta-analyses consistently show modest but measurable increases in total cholesterol and low-density lipoprotein cholesterol in patients with SCH. Importantly, levothyroxine treatment modestly lowers low-density lipoprotein in patients with SCH — with the effect most pronounced in those with thyroid-stimulating hormone above 10 mIU/L. For patients already managing cardiovascular risk, this metabolic effect of SCH is worth factoring into treatment decisions.

Heart Failure Risk

A 2012 individual-participant analysis of 6 cohorts (25,390 people) from the Thyroid Studies Collaboration found heart-failure risk about 1.9 times higher (hazard ratio 1.86) at a thyroid-stimulating hormone of 10 to 19.9 mIU/L; the increase was not significant at lower levels. The mechanism is plausible: thyroid hormones are critical for maintaining cardiac contractility, heart rate, and vascular tone. Even compensated thyroid underactivity may subtly impair cardiac function over time.

Coronary Artery Disease

The picture here is nuanced and age-dependent. A landmark 2010 analysis from the Thyroid Studies Collaboration, pooling individual participant data from more than 55,000 adults, found that the risk of coronary heart disease events rose with higher thyroid-stimulating hormone, most clearly at 10 to 19.9 mIU/L (hazard ratio 1.89); in that analysis the risks did not differ significantly by age. An earlier 2008 meta-analysis by Razvi and colleagues did find an age split: excess coronary artery disease (CAD) risk in studies of people younger than 65, but not in studies of people 65 and older. One plausible explanation for that split is that in older adults, atherosclerosis is already established from decades of other risk factors, and the marginal contribution of a modestly elevated thyroid-stimulating hormone is too small to stand out.

Atrial Fibrillation

SCH itself does not appear to meaningfully increase atrial fibrillation risk — that risk is primarily associated with low thyroid-stimulating hormone (hyperthyroidism or overtreatment with thyroid hormones). This is clinically important because it means overtreatment of SCH — pushing thyroid-stimulating hormone below 0.1 mIU/L — is arguably more dangerous for atrial fibrillation than the SCH itself. In elderly patients, this risk of over-replacement is a major argument for watchful waiting and conservative dosing.

Summary: Who Is at Cardiovascular Risk

The cardiovascular argument for treatment is strongest in: patients with thyroid-stimulating hormone above 10 mIU/L, adults under 65, and those with existing cardiovascular risk factors (hypertension, dyslipidemia, smoking, family history). In older adults with mild SCH, cardiovascular risk reduction is not a clear benefit of treatment.

Back to Table of Contents

To Treat or Not to Treat — The Central Debate

No question in thyroid medicine generates more disagreement than whether to treat mild subclinical hypothyroidism. Here is what the evidence actually supports.

When to Treat — Clearer Cases

• Thyroid-stimulating hormone above 10 mIU/L: Most major guidelines — American Thyroid Association, European Thyroid Association, American Association of Clinical Endocrinologists — agree that treatment is appropriate at this level. The cardiovascular and metabolic risks are better established, and progression to overt hypothyroidism is more likely.
• Pregnancy or planning to conceive: The stakes are highest here. Maternal thyroid hormones are critical for fetal brain development in the first trimester, before the fetal thyroid is active. See the Pregnancy section below for specifics.
• Symptoms clearly attributable to thyroid dysfunction: When objective findings — bradycardia, elevated cholesterol, myxedema on exam — accompany elevated thyroid-stimulating hormone, the case for treatment is stronger.
• Positive TPO antibodies with thyroid-stimulating hormone above 4.5: TPO positivity predicts faster progression to overt hypothyroidism. Many clinicians treat earlier in this group.
• Younger adults (under 65) with cardiovascular risk factors: The data on reduced cardiovascular risk with treatment is most relevant for this age group.

When Watchful Waiting Is Reasonable

• Thyroid-stimulating hormone 4.5 to 10 mIU/L, age 65 or older, asymptomatic: This is the group for whom the TRUST trial most clearly showed no benefit from treatment.
• Single elevated thyroid-stimulating hormone not yet confirmed: Guidelines call for a repeat test before treatment. Up to half of mildly elevated thyroid-stimulating hormone values normalize on repeat testing.
• Transient cause identified: Postpartum thyroiditis or recovery from illness; observation for 3 to 6 months is usual.

The TRUST Trial — The Most Important Study

Published in the New England Journal of Medicine in 2017, the Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism Trial (TRUST) enrolled 737 community-dwelling adults aged 65 and older with persistent SCH (TSH 4.60 to 19.99 mIU/L). Participants were randomized to levothyroxine titrated to normalize thyroid-stimulating hormone, or matching placebo, and followed for one to three years. The primary outcome was symptom score on the validated ThyPRO questionnaire.

Result: there was no difference between the levothyroxine and placebo groups on the ThyPRO score, on tiredness, on a measure of fatigue, or on quality of life. Thyroid-stimulating hormone normalized in the treatment group, confirming that the drug worked biochemically — but patients felt no better. The TRUST trial dealt a significant blow to the routine treatment of SCH in older adults with mild thyroid-stimulating hormone elevation.

The 2018 Meta-Analysis and the 2019 BMJ Guideline

A 2018 systematic review and meta-analysis in JAMA (Feller and colleagues) pooled 21 randomized trials with 2,192 nonpregnant adults and found that thyroid hormone therapy lowered thyroid-stimulating hormone but was not associated with improvements in general quality of life or thyroid-related symptoms; the authors wrote that the findings do not support routine treatment. Building on that review, a 2019 BMJ clinical practice guideline panel (Bekkering and colleagues) issued a strong recommendation against thyroid hormones for adults with SCH, noting that it does not apply to pregnant women, people with thyroid-stimulating hormone above 20 mIU/L, and may not apply to people with severe symptoms or young adults (about 30 or younger).

Individualizing the Decision

A 45-year-old with thyroid-stimulating hormone of 7, positive TPO antibodies, fatigue that is measurably worse than her pre-illness baseline, and a family history of heart disease is a very different patient from a 78-year-old with thyroid-stimulating hormone of 6, no symptoms, and no cardiovascular risk factors. The same lab value does not call for the same management in every patient. Guidelines weigh age, symptom burden, antibody status, thyroid-stimulating hormone trajectory over time, pregnancy status, and cardiovascular risk profile.

Back to Table of Contents

Pregnancy and Subclinical Hypothyroidism

Subclinical hypothyroidism during pregnancy carries higher stakes than in any other clinical context. Maternal thyroid hormones — transferred across the placenta — are the only source of thyroid hormone for the developing fetus until the fetal thyroid becomes active at approximately 12 weeks of gestation. During this critical window, adequate maternal thyroid hormone is essential for normal fetal brain development.

What the Evidence Shows

Observational studies have consistently associated maternal SCH with increased risks of miscarriage, preterm birth, low birth weight, and impaired neurodevelopmental outcomes in children. The data are strongest for women with both elevated thyroid-stimulating hormone and positive TPO antibodies — that combination appears to carry the highest risk of adverse pregnancy outcomes.

Trimester-Specific Thyroid-Stimulating Hormone Thresholds

During normal pregnancy, thyroid-stimulating hormone naturally falls in the first trimester because human chorionic gonadotropin (hCG) — the hormone responsible for a positive pregnancy test — stimulates the thyroid directly through mild cross-reactivity with the thyroid-stimulating hormone receptor. This means the normal thyroid-stimulating hormone range is lower in the first trimester than in non-pregnant women. Population-specific and trimester-specific reference ranges are the standard during pregnancy:

• First trimester: Many institutions use an upper limit of approximately 4.0 mIU/L; the 2017 American Thyroid Association guidelines moved away from the prior 2.5 mIU/L cutoff toward population-specific upper limits, typically in the 4.0 range.
• Second trimester: Upper limit approximately 4.0 to 4.5 mIU/L (returns closer to non-pregnant reference).
• Third trimester: Similar to second trimester.

2017 ATA Pregnancy Guidelines — Treatment Thresholds

• Treatment is recommended when thyroid-stimulating hormone is above the pregnancy-specific upper limit and TPO antibodies are positive.
• Treatment should be considered when thyroid-stimulating hormone is above 4.0 mIU/L regardless of antibody status.
• When thyroid-stimulating hormone is between 2.5 and 4.0 mIU/L and TPO antibodies are positive, treatment may be considered; monitoring is also acceptable.

Thyroid-Stimulating Hormone Targets During Pregnancy

• First trimester: thyroid-stimulating hormone 0.5 to 2.5 mIU/L
• Second and third trimesters: thyroid-stimulating hormone 0.5 to 3.0 mIU/L

Monitoring and Practical Points

Women already on levothyroxine who become pregnant typically need a 25 to 30 percent dose increase immediately — often implemented as taking two extra doses per week right away, before the first prenatal visit. Thyroid function is usually checked every 4 weeks throughout the first trimester and once in the second trimester. Women with a history of SCH or Hashimoto's usually have thyroid-stimulating hormone checked as early as possible in pregnancy, ideally in the first weeks, and the levothyroxine dose of women with previously treated hypothyroidism is usually adjusted promptly when pregnancy is confirmed.

Back to Table of Contents

Levothyroxine Treatment — Practical Guide

When subclinical hypothyroidism is treated, the usual approach is to start levothyroxine at a low dose and titrate carefully — unlike overt hypothyroidism, where full replacement dosing is usually needed from the start.

Starting Dose

• Most adults: Starting doses of 25 to 50 mcg per day are typical (the TRUST trial started at 50 mcg, or 25 mcg for people under 50 kg or with coronary heart disease). A modest dose is used because thyroid-stimulating hormone is only mildly elevated and the thyroid is still contributing.
• Elderly patients or those with heart disease: Starting doses of 12.5 to 25 mcg per day, increased very slowly, are typical. Even small amounts of excess thyroid hormone can trigger angina or arrhythmia in vulnerable patients.
• Pregnancy: About 50 mcg per day is a typical start, with a quick increase for women already on a lower dose.

Titration

Doses are usually raised by 12.5 to 25 mcg every 4 to 6 weeks, guided by repeat thyroid-stimulating hormone measurement. Thyroid-stimulating hormone takes at least 6 weeks to fully reflect a dose change — checking it sooner gives a misleading result. Dose changes are normally based on a confirming thyroid-stimulating hormone result rather than on symptoms alone.

Thyroid-Stimulating Hormone Targets

• Most adults: thyroid-stimulating hormone 1.0 to 3.0 mIU/L
• Younger patients (under 50): thyroid-stimulating hormone 0.5 to 2.0 mIU/L may be preferred
• Elderly patients (65 and older): thyroid-stimulating hormone 1.0 to 4.0 mIU/L — a slightly higher target is deliberate because over-replacement in this age group causes more harm than a modestly elevated thyroid-stimulating hormone
• Pregnancy: See Pregnancy section above

The Critical Danger: Overtreatment

A suppressed thyroid-stimulating hormone below 0.1 mIU/L — whether from over-replacement or taking more medication than prescribed — significantly increases the risk of:

• Atrial fibrillation: A 2 to 3-fold increased risk in older adults with thyroid-stimulating hormone below 0.1
• Osteoporosis: Thyroid hormones stimulate bone resorption; excess replacement accelerates bone loss, particularly in postmenopausal women not taking calcium and vitamin D
• Anxiety, palpitations, and insomnia

In patients over 65, the risks of over-replacement are not theoretical — they are well-documented. This is a major reason why watchful waiting is preferred for older patients with mild SCH.

Practical Dosing Details

• Timing: The levothyroxine label directs once-daily dosing, preferably on an empty stomach, one-half to one hour before breakfast with a full glass of water. Coffee — including black coffee — can reduce absorption, and a gap of at least 30 minutes is the usual practice. Some patients find taking it at bedtime (at least 3 to 4 hours after the last meal) achieves slightly better thyroid-stimulating hormone suppression.
• Drug interactions: Calcium supplements, iron supplements, antacids (especially calcium carbonate), and proton pump inhibitors all reduce levothyroxine absorption. The label directs taking levothyroxine at least 4 hours before or after drugs known to interfere with its absorption.
• Soy foods and large amounts of high-fiber foods can also modestly reduce absorption when eaten close to the dose; the label names soybean flour, walnuts and dietary fiber.
• Brand vs. generic: Levothyroxine products are bioequivalent by U.S. Food and Drug Administration (FDA) standards, but some patients with sensitivity to small dose differences do better staying on one consistent product — either always the same generic or always the same brand-name product.
• Monitoring once stable: Thyroid-stimulating hormone is usually checked annually once the dose is stable, and sooner if symptoms change, pregnancy occurs, or significant weight changes happen.

Back to Table of Contents

Monitoring Without Treatment — Watchful Waiting Protocol

For many patients with subclinical hypothyroidism — especially those with thyroid-stimulating hormone between 4.5 and 10 mIU/L and no pressing symptoms, or those aged 65 and older — watchful waiting with regular monitoring is the most evidence-based approach. Here is how it works in practice.

Confirming the Diagnosis First

Before any management plan is made, the elevated thyroid-stimulating hormone needs to be confirmed on repeat testing at least 3 months after the first result. This single step eliminates a large proportion of apparent SCH diagnoses — transient causes, lab variation, timing factors. The repeat test includes free T4. If thyroid-stimulating hormone normalizes, the usual follow-up is annual monitoring only.

Baseline Testing

Once SCH is confirmed, baseline testing usually covers:

• TPO antibodies and anti-thyroglobulin antibodies (to assess Hashimoto's risk and progression likelihood)
• Free T4 (to confirm normal)
• A full lipid panel (to document baseline cardiovascular risk)

Ongoing Monitoring Schedule

• Every 3 to 6 months initially, until thyroid-stimulating hormone is confirmed stable over two consecutive measurements
• Annually thereafter if thyroid-stimulating hormone remains below 10 and stable
• Recheck sooner if symptoms develop, pregnancy is planned, or a new medication known to affect thyroid function is started

When to Start Treatment During Follow-Up

Guidelines and clinicians generally describe moving to treatment when:

• Thyroid-stimulating hormone rises above 10 mIU/L on any repeat measurement
• Thyroid-stimulating hormone is persistently above 7 to 8 mIU/L across multiple measurements in a younger patient
• The patient develops clear, new symptoms that are plausibly thyroid-related
• Pregnancy is confirmed or being actively pursued
• New cardiovascular risk factors emerge that shift the risk-benefit calculus toward treatment

Reassurance That Matters

Patients on watchful waiting often feel anxious about their "untreated" thyroid condition. Several evidence-based reassurances are worth communicating clearly: a thyroid-stimulating hormone of 5 or 6 does not mean your thyroid is failing — it means it is working harder than ideal but still succeeding. The majority of people in this thyroid-stimulating hormone range have no measurable impairment in physical or cognitive function. In older adults especially, a slightly elevated thyroid-stimulating hormone may actually be protective — population studies have suggested that older adults with mildly elevated thyroid-stimulating hormone live longer on average than those with low-normal thyroid-stimulating hormone. Overtreatment harms are real; not treating is a legitimate, evidence-based choice.

Back to Table of Contents

Nutritional and Lifestyle Factors

While nutritional and lifestyle interventions cannot replace thyroid hormone when it is truly deficient, several factors meaningfully influence thyroid function, autoimmune activity, and symptom burden in people with subclinical hypothyroidism.

Iodine — Enough But Not Too Much

Iodine is the raw material from which thyroid hormones are made. Deficiency causes hypothyroidism; this remains a public health concern in parts of the world where iodized salt is not used. However, for most people in the United States — where iodized salt and dairy provide adequate intake — adding supplemental iodine is unnecessary and potentially harmful. Very high iodine intake (above 500 mcg per day) can paradoxically worsen thyroid function in people with underlying autoimmune thyroid disease through the Wolff-Chaikoff effect. Kelp and seaweed supplements in particular can deliver wildly variable and sometimes extremely high iodine doses. In people with Hashimoto's or confirmed subclinical hypothyroidism, mega-dose iodine supplements and high-dose kelp are the main sources of this risk.

Selenium

Selenium is essential for the enzymes that convert T4 to the active T3 form and for the antioxidant enzyme glutathione peroxidase, which protects the thyroid gland from oxidative damage during hormone synthesis. Meta-analyses have shown that selenium supplementation (100 to 200 mcg of selenomethionine daily) significantly reduces TPO antibody titers in patients with Hashimoto's thyroiditis — and may slow the progression of autoimmune thyroid damage. While selenium supplementation does not treat hypothyroidism directly, it is used as an adjunct by many practitioners for Hashimoto's-related SCH. Food sources include Brazil nuts (one or two per day provides roughly 100 mcg), tuna, sardines, and eggs.

Vitamin D

Vitamin D deficiency has been consistently associated with autoimmune thyroid disease, including Hashimoto's. The immune-modulating effects of vitamin D may reduce autoimmune activity in susceptible individuals. Some practitioners aim for a 25-hydroxyvitamin D level above 40 ng/mL in autoimmune thyroid disease and describe 1,000 to 2,000 international units (IU) of vitamin D3 daily as the amount most adults need to reach it, though individual needs vary. Practitioners commonly test baseline 25-hydroxyvitamin D in people with confirmed SCH and Hashimoto's.

Goitrogenic Foods — Less Concern Than Often Claimed

Cruciferous vegetables — broccoli, kale, cabbage, Brussels sprouts, bok choy — contain compounds called glucosinolates that, in very large amounts consumed raw, can mildly inhibit thyroid iodine uptake. This effect has been dramatically overstated in popular health media. Cooking destroys most glucosinolates. Normal amounts of cooked cruciferous vegetables have not been shown to harm people with SCH or Hashimoto's. Only extraordinary quantities of raw cruciferous vegetables — quantities that would be difficult to consume in any realistic diet — have been associated with measurable effects on thyroid function.

Soy

Soy isoflavones can modestly inhibit thyroid peroxidase and may interfere with levothyroxine absorption when consumed close to the time of the dose. For patients not on medication, normal dietary soy intake is unlikely to cause problems in iodine-sufficient individuals. For people on levothyroxine, the usual practice is to separate soy foods from the dose by at least 4 hours — the same gap the label sets for calcium and iron.

Stress and Cortisol

Chronic psychological stress elevates cortisol, which inhibits the conversion of T4 to the more active T3 and suppresses thyroid-stimulating hormone release at the pituitary level. This may partially explain why many patients feel worse thyroid-symptom-wise during high-stress periods even when their thyroid-stimulating hormone is stable. While cortisol management is not a primary treatment for SCH, stress reduction — through sleep, exercise, mindfulness, or whatever sustainable approach works for the individual — addresses a real physiological interaction.

Sleep

Observational studies have found associations between poor sleep quality and higher thyroid-stimulating hormone levels, as well as between sleep deprivation and lower T3. Thyroid-stimulating hormone peaks during the early hours of sleep, and disrupted sleep architecture may alter thyroid axis regulation. Prioritizing adequate, consistent sleep is worthwhile for overall endocrine health — including thyroid function.

Exercise

Moderate aerobic exercise has been shown in small studies to modestly improve thyroid function and reduce thyroid-stimulating hormone in patients with hypothyroid spectrum conditions. Exercise also addresses many of the non-specific symptoms that overlap with SCH — fatigue, weight gain, depression — making it valuable regardless of its direct thyroid effects.

Back to Table of Contents

Key Research Papers

1. Stott DJ, Rodondi N, Kearney PM, et al. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism (TRUST Trial). N Engl J Med. 2017;376(26):2534–2544. — The landmark RCT of 737 adults 65+ with SCH (TSH 4.60–19.99). Levothyroxine normalized TSH but produced no improvement in symptoms, tiredness, or quality of life compared to placebo. Fundamentally changed guidelines on treating SCH in older adults. — PubMed PMID: 28402245
2. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291(2):228–238. — Foundational evidence-based review establishing the framework for diagnosing and managing SCH; defined staging by TSH level and reviewed evidence on cardiovascular and metabolic risks. — PubMed PMID: 14722150
3. Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J. 2013;2(4):215–228. — European Thyroid Association clinical guidelines; recommends treatment for TSH >10 in all ages, advocates individualized approach for TSH 4.5–10; framework still widely used. — PubMed PMID: 24783053
4. Rodondi N, den Elzen WP, Bauer DC, et al; Thyroid Studies Collaboration. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304(12):1365–1374. — Individual-participant meta-analysis of 55,287 adults: coronary heart disease events and coronary deaths rose with higher TSH, particularly for TSH 10–19.9; total mortality was not increased, and risks did not differ significantly by age, sex, or preexisting cardiovascular disease. — PubMed PMID: 20858880
5. Razvi S, Shakoor A, Vanderpump M, Weaver JU, Pearce SH. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a metaanalysis. J Clin Endocrinol Metab. 2008;93(8):2998–3007. — Confirmed age-dependent cardiovascular risk in SCH; significant ischemic heart disease risk in patients under 65, but not in older age groups. — PubMed PMID: 18505765
6. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315–389. — Current ATA pregnancy-specific thyroid guidelines; defines trimester-specific TSH cutoffs, treatment thresholds, and monitoring protocols for SCH in pregnancy. — PubMed PMID: 28056690
7. Gussekloo J, van Exel E, de Craen AJ, et al. Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004;292(21):2591–2599. — Paradoxically, older adults (85+) with higher TSH had better survival; raises important questions about whether mildly elevated TSH in the elderly is harmful or even protective. — PubMed PMID: 15572717
8. Razvi S, Weaver JU, Butler TJ, Pearce SH. Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. Arch Intern Med. 2012;172(10):811–817. — Observational study showing levothyroxine treatment of SCH was associated with reduced ischemic heart disease events in adults under 70 but not in older patients. — PubMed PMID: 22529180
9. Gencer B, Collet TH, Virgini V, et al; Thyroid Studies Collaboration. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation. 2012;126(9):1040–1049. — 25,390 participants; heart-failure risk raised at TSH 10–19.9 mIU/L (hazard ratio 1.86). — PubMed PMID: 22821943
10. Feller M, Snel M, Moutzouri E, et al. Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic review and meta-analysis. JAMA. 2018;320(13):1349–1359. — 21 randomized trials, 2,192 adults; no improvement in general quality of life or thyroid-related symptoms. — PubMed PMID: 30285179
11. Bekkering GE, Agoritsas T, Lytvyn L, et al. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ. 2019;365:l2006. — Strong recommendation against thyroid hormones for most adults with SCH (not pregnant women or TSH >20 mIU/L). — PubMed PMID: 31088853
12. Toulis KA, Anastasilakis AD, Tzellos TG, Goulis DG, Kouvelas D. Selenium supplementation in the treatment of Hashimoto's thyroiditis: a systematic review and a meta-analysis. Thyroid. 2010;20(10):1163–1173. — Meta-analysis showing selenium supplementation significantly reduces TPO antibody levels in Hashimoto's thyroiditis; supports its use as an adjunct in autoimmune SCH. — PubMed PMID: 20883174
13. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29(1):76–131. — Comprehensive review of subclinical thyroid dysfunction including epidemiology, natural history, associations with symptoms and systemic disease, and treatment evidence across the TSH spectrum. — PubMed PMID: 17991805
14. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012;22(12):1200–1235. — Joint AACE/ATA clinical guidelines covering diagnosis, staging, and treatment thresholds for SCH; practical reference for clinical decision-making. — PubMed PMID: 22954017

PubMed Topic Searches

1. Subclinical hypothyroidism treatment levothyroxine — PubMed
2. Subclinical hypothyroidism pregnancy outcomes — PubMed
3. Subclinical hypothyroidism cardiovascular risk meta-analysis — PubMed
4. Selenium Hashimoto's thyroiditis TPO antibodies — PubMed

Back to Table of Contents

Featured Videos

Connections

• Endocrinology
• Hypothyroidism
• Hashimoto's Thyroiditis
• Graves' Disease
• Thyroid Disorders
• Thyroid Storm
• Thyroid Cancer
• Goiter
• Hyperthyroidism
• Polycystic Ovary Syndrome (PCOS)
• Gestational Diabetes
• Selenium
• Vitamin D
• Iodine
• Lab Tests

Back to Table of Contents